Bicocca Open Archive

Logo unimib boa
RUPERTO, NICOLINO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 30.766
NA - Nord America 12.449
EU - Europa 9.121
SA - Sud America 4.938
Continente sconosciuto - Info sul continente non disponibili 1.698
AF - Africa 624
OC - Oceania 244
Totale 59.840
Salva come PNG Salva come JPEG
Nazione #
VN - Vietnam 12.612
US - Stati Uniti d'America 10.928
SG - Singapore 6.103
CN - Cina 4.637
IT - Italia 3.925
BR - Brasile 3.457
HK - Hong Kong 1.857
BD - Bangladesh 1.397
RU - Federazione Russa 835
TR - Turchia 758
MX - Messico 742
FR - Francia 699
KR - Corea 687
DE - Germania 622
ES - Italia 620
IN - India 604
CA - Canada 501
AR - Argentina 490
GB - Regno Unito 410
ID - Indonesia 402
JP - Giappone 375
FI - Finlandia 325
CO - Colombia 297
AU - Australia 222
NL - Olanda 209
EC - Ecuador 190
IQ - Iraq 180
PK - Pakistan 179
SA - Arabia Saudita 177
AT - Austria 176
PL - Polonia 167
CL - Cile 164
ZA - Sudafrica 144
VE - Venezuela 117
PH - Filippine 116
GR - Grecia 110
CH - Svizzera 109
EG - Egitto 108
PT - Portogallo 106
SE - Svezia 105
UA - Ucraina 97
CZ - Repubblica Ceca 91
MA - Marocco 88
PE - Perù 85
PY - Paraguay 72
KZ - Kazakistan 69
UZ - Uzbekistan 69
TW - Taiwan 64
IL - Israele 62
DZ - Algeria 61
RO - Romania 61
MY - Malesia 60
NO - Norvegia 60
TN - Tunisia 60
CR - Costa Rica 58
HU - Ungheria 49
TH - Thailandia 48
BE - Belgio 46
KE - Kenya 45
AE - Emirati Arabi Uniti 44
JM - Giamaica 44
HR - Croazia 38
SK - Slovacchia (Repubblica Slovacca) 37
MD - Moldavia 36
GT - Guatemala 34
BO - Bolivia 33
JO - Giordania 33
NP - Nepal 33
HN - Honduras 30
UY - Uruguay 30
ET - Etiopia 29
IE - Irlanda 29
DO - Repubblica Dominicana 28
AZ - Azerbaigian 27
LT - Lituania 25
OM - Oman 24
SI - Slovenia 24
DK - Danimarca 23
NZ - Nuova Zelanda 21
LB - Libano 19
AL - Albania 18
RS - Serbia 17
SN - Senegal 17
PS - Palestinian Territory 15
NI - Nicaragua 14
TT - Trinidad e Tobago 14
GE - Georgia 13
SV - El Salvador 13
SY - Repubblica araba siriana 13
PR - Porto Rico 12
BY - Bielorussia 11
IR - Iran 11
NG - Nigeria 11
EE - Estonia 10
LV - Lettonia 10
PA - Panama 10
AM - Armenia 9
AO - Angola 9
KG - Kirghizistan 9
LK - Sri Lanka 9
Totale 57.993
Salva come PNG Salva come JPEG
Città #
Ho Chi Minh City 4.028
Hanoi 3.222
Singapore 2.631
Hong Kong 1.785
San Jose 1.709
Hefei 1.647
Ashburn 1.130
Milan 1.095
Council Bluffs 664
Seoul 639
Chicago 559
Rome 518
Los Angeles 465
Lauterbourg 397
New York 377
Da Nang 351
Haiphong 343
São Paulo 335
Dallas 323
Buffalo 310
The Dalles 304
Ha Long 291
Quận Bình Thạnh 247
Biên Hòa 246
Helsinki 244
Istanbul 235
Hải Dương 210
Beijing 209
Ninh Bình 198
Santa Clara 193
Thái Nguyên 191
Vũng Tàu 177
Can Tho 173
Melbourne 173
Moscow 168
Rio de Janeiro 151
Ankara 148
Bắc Ninh 145
Madrid 140
Jakarta 124
Bắc Giang 120
Figino 120
Boardman 119
Frankfurt am Main 115
Naples 113
Quận Một 113
Tokyo 111
Mexico City 108
Phủ Lý 107
Shanghai 107
Montreal 106
Quận Phú Nhuận 106
Toronto 102
Bogotá 98
Guangzhou 94
Turin 91
Quận Sáu 88
Santiago 82
Thái Bình 79
Brasília 78
Phoenix 78
Barcelona 77
Vinh 77
Genoa 76
Curitiba 75
Baghdad 74
London 74
Quito 74
Vienna 74
Buenos Aires 72
Lấp Vò 72
Bologna 71
Medellín 71
Atlanta 70
Riyadh 70
Jeddah 69
Paris 69
Quận Tân Phú 69
Belo Horizonte 68
Lang Son 68
Uyen Hung 68
Guadalajara 66
Lima 65
Điện Bàn 65
Dhaka 63
Karachi 62
Palermo 62
Porto Alegre 62
Hangzhou 61
Philadelphia 60
Amsterdam 59
Nuremberg 59
Vĩnh Tường 59
Quận Năm 58
Tashkent 58
Brooklyn 56
Houston 56
Manchester 55
Quảng Ninh 55
Thu Dau Mot 55
Totale 31.204
Salva come PNG Salva come JPEG
Nome #
Juvenile idiopathic arthritis 4.303
Classification criteria for autoinflammatory recurrent fevers 2.601
Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial 1.440
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial 1.134
Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis 676
The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist 553
Methotrexate therapy in refractory pediatric onset systemic lupus erythematosus 492
Validation of the PEDiatric Behçet’s Disease classification criteria: an evidence-based approach 436
Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2-5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept 429
Persistence of disease flares is associated with an inadequate colchicine dose in familial Mediterranean fever: A national multicenter longitudinal study 424
Two-year efficacy and safety of etanercept in pediatric patients with extended oligoarthritis, enthesitisrelated arthritis, or psoriatic arthritis 415
Performance of the Birmingham Vasculitis Activity Score and Disease Extent Index in childhood vasculitides 415
The Italian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 397
Macrophage Activation Syndrome in Juvenile Systemic Lupus Erythematosus A Multinational Multicenter Study of Thirty-Eight Patients 397
Macrophage activation syndrome in juvenile systemic lupus erythematosus: an under-recognized complication? 394
The Bulgarian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 387
Is it worth including subtalar joint in ultrasound ankle assessment of patients with juvenile idiopathic arthritis? 379
The Korean version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 379
The Dutch version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 377
EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation 367
Is It Time to Move to Active Comparator Trials in Juvenile Idiopathic Arthritis? A Review of Current Study Designs 360
Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa: An Open-Label, Randomized, Bayesian Noninferiority Trial 356
Factors associated with response to methotrexate in systemic-onset juvenile chronic arthritis 348
Criteria to define response to therapy in paediatric rheumatic diseases 347
Localized scleroderma in childhood is not just a skin disease 334
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects 282
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 276
Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results 272
The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist 271
Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial 264
Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases 263
Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy 261
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 258
Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis 243
Correction to: The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (Rheumatology International, (2018), 38, S1, (251-258), 10.1007/s00296-018-3960-1) 241
The Russian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 235
Adapted versions of the Sharp/van der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis 235
Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis 233
Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR project 232
Do the Provisional Paediatric Rheumatology International Trials Organisation Enthesitis/Spondylitis-Related Juvenile Idiopathic Arthritis Criteria Capture Youth With Axial Spondyloarthritis? 231
Factors for Consideration by Pediatric Rheumatologists When Scoring the Physician Global Assessment of Disease Activity in Juvenile Idiopathic Arthritis: First Step Toward an Internal Consensus 230
Discordance between proxy-reported and observed assessment of functional ability of children with juvenile idiopathic arthritis 226
Performance of different diagnostic criteria for familial Mediterranean fever in children with periodic fevers: Results from a multicenter international registry 224
Is minimal clinically important difference relevant for the interpretation of clinical trials in pediatric rheumatic diseases? 220
Use of the Sharp and Larsen scoring methods in the assessment of radiographic progression in juvenile idiopathic arthritis 219
Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicenter PRINTO study 219
The Argentinian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 216
2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation collaborative initiative 214
Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus 212
Parent and Child Acceptable Symptom State in Juvenile Idiopathic Arthritis 211
Towards the definition of disease phenotypes in paediatric SAPHO syndrome: a national multicentric study 210
Defining criteria for disease activity states in juvenile dermatomyositis based on the Juvenile Dermatomyositis Activity Index 210
An International Consensus Survey of Diagnostic Criteria for Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis 205
Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial 204
Classification Criteria for Axial Disease in Youth With Juvenile Spondyloarthritis 200
Validation of the Childhood Health Assessment Questionnaire in active juvenile systemic lupus erythematosus 200
Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study 197
Effect of Characteristic Inflammatory and Structural Pelvic Magnetic Resonance Imaging Lesions on Expert Assessment of Axial Juvenile Spondyloarthritis 195
Clinical insights into heterogeneity of rheumatoid factor negative polyarticular juvenile idiopathic arthritis across the world 191
Ethics bureaucracy: a significant hurdle for collaborative follow-up of drug effectiveness in rare childhood diseases 186
Juvenile arthritis management in less resourced countries (JAMLess): consensus recommendations from the Cradle of Humankind 183
The Dutch version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 181
The Bulgarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 180
Measures of Adult and Juvenile Dermatomyositis, Polymyositis, and Inclusion Body Myositis Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), Physician Global Damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI) 180
Development and initial validation of parent and child versions of the Juvenile Arthritis Disease Activity Score 179
Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: Preliminary results of an open-label, long-term extension study 178
Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis 176
Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study 176
Monitoring of Adverse Events and Safety in Autoinflammatory Diseases: Real-Life Data from the Eurofever Registry 175
A randomized trial of parenteral methotrexate comparing an intermediate with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate 174
Relative responsiveness of condition specific and generic health status measures in juvenile idiopathic arthritis 173
Clinical features, treatment and outcomes of Italian children with enthesitis-related arthritis and juvenile psoriatic arthritis: a cross-sectional cohort study 172
Biomarker Changes in Response to Tofacitinib Treatment in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis 171
Adalimumab in Juvenile Rheumatoid Arthritis Reply 171
Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: Results from the 5-year long-term extension of the phase III pivotal trials 169
Responsiveness of clinical measures to flare of disease activity in juvenile idiopathic arthritis 169
2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 167
S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis 166
Transcriptional Profiling of Tofacitinib Treatment in Juvenile Idiopathic Arthritis: Implications for Treatment Response Prediction 166
Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis 165
Physician's global assessment of disease activity in juvenile idiopathic arthritis: consensus-based recommendations from an international task force 162
The Paediatric Rheumatology International Trials Organisation Provisional Criteria for the Evaluation of Response to Therapy in Juvenile Dermatomyositis 161
Tapering Canakinumab Monotherapy in Patients with Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results from an Open‐label, Randomized Phase IIIb/IV Study 161
Thrombotic manifestations in pediatric Behcet syndrome: A multicenter comparative study from the EUROFEVER registry 157
Long-term efficacy and safety of colchicine and anti-IL-1 blockers in FMF: results from the Eurofever multicenter observational study 155
Safety and effectiveness of abatacept in juvenile idiopathic arthritis: Results from the PRINTO/PRCSG registry 153
TNFRSF1A-pR92Q variant identifies a subset of patients more similar to systemic undifferentiated recurrent fever than TNF receptor-associated periodic syndrome 152
The Provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: A prospective validation study 151
Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis 149
Performance of the 2016 ACR-EULAR myositis response criteria in juvenile dermatomyositis therapeutic trials and consensus profiles 146
Clinical trials in children and adolescents with systemic lupus erythematosus: Methodological aspects, regulatory landscape and future opportunities 144
Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score 144
Development and validation of a composite disease activity score for juvenile idiopathic arthritis 143
Patient-Reported Outcomes Among Patients Ages Two to Seventeen Years With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Subcutaneous Abatacept: Two-Year Results From an International Phase III Study 142
Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries 141
JIA, Today and Tomorrow 140
Periodic fever syndromes in Eastern and Central European countries: results of a pediatric multinational survey 139
Porpora di Schönlein-Henoch in paziente con pregressa glomerulonefrite di Berger (Schönlein-Henoch purpura in patients with previous Berger's glomerulonephritis) 138
Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use 136
Summary of Research: Ten-Year Safety and Clinical Benefit from Open-Label Etanercept Treatment in Children and Young Adults with Juvenile Idiopathic Arthritis 136
Totale 32.547
Salva come PNG Salva come JPEG
Categoria #
all - tutte 134.468
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 134.468
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/202510.043 0 0 0 0 605 129 1.200 822 1.717 1.474 1.228 2.868
2025/202644.632 10.069 7.688 3.113 4.583 1.858 1.286 3.311 1.998 2.212 2.449 2.400 3.665
2026/20275.165 2.036 1.899 1.230 0 0 0 0 0 0 0 0 0
Totale 59.840